11.73

2.13% 0.2439

Keros Therapeutics Inc (KROS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché KROS Giù? Forum Previsione

Precedente Chiudi:

$11.49

Aprire:

$11.41

Volume 24 ore:

82,786

Relative Volume:

0.21

Capitalizzazione di mercato:

$232.31M

Reddito:

$244.06M

Utile/perdita netta:

$87.01M

Rapporto P/E:

6.4426

EPS:

1.8213

Flusso di cassa netto:

$105.95M

1 W Prestazione:

+6.58%

1M Prestazione:

-2.21%

6M Prestazione:

-24.54%

1 anno Prestazione:

-19.90%

Intervallo 1D:

$11.41

$12.07

Intervallo di 1 settimana:

$10.88

$12.07

Portata 52W:

$10.41

$22.55

Keros Therapeutics Inc Stock (KROS) Company Profile

Nome

Keros Therapeutics Inc

Settore

Healthcare (1112)

Industria

Biotechnology (622)

Telefono

617-314-6297

Indirizzo

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Dipendente

Cinguettio

Prossima data di guadagno

2026-05-05

Ultimi documenti SEC

KROS's Discussions on Twitter

Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KROS Keros Therapeutics Inc	11.74	227.36M	244.06M	87.01M	105.95M	1.8213
VRTX Vertex Pharmaceuticals Inc	426.31	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	709.50	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	800.14	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.46	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.77	32.66B	5.36B	287.73M	924.18M	2.5229

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-06-10	Downgrade	BofA Securities	Buy → Neutral
2025-01-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-17	Downgrade	Wedbush	Outperform → Neutral
2024-12-16	Downgrade	Guggenheim	Buy → Neutral
2024-12-16	Reiterato	Oppenheimer	Outperform
2024-12-13	Reiterato	H.C. Wainwright	Buy
2024-12-12	Downgrade	BTIG Research	Buy → Neutral
2024-12-12	Downgrade	TD Cowen	Buy → Hold
2024-12-12	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-05	Iniziato	Jefferies	Buy
2024-10-24	Iniziato	Cantor Fitzgerald	Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-23	Iniziato	Guggenheim	Buy
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-02-21	Iniziato	William Blair	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-07-31	Iniziato	Wedbush	Outperform
2023-07-26	Iniziato	BofA Securities	Buy
2023-02-14	Iniziato	Cowen	Outperform
2022-10-18	Iniziato	Truist	Buy
2022-07-26	Iniziato	BTIG Research	Buy
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-05-04	Iniziato	H.C. Wainwright	Buy
2020-05-04	Iniziato	Jefferies	Buy
2020-05-04	Iniziato	Piper Sandler	Overweight
2020-05-04	Iniziato	SVB Leerink	Outperform

Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

May 02, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat

May 02, 2026

May 01, 2026

KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN

May 01, 2026

Apr 29, 2026

Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart

Apr 29, 2026

Apr 28, 2026

Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

Apr 22, 2026

[ARS] Keros Therapeutics, Inc. SEC Filing - Stock Titan

Apr 22, 2026

Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return - Stock Titan

Apr 22, 2026

KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 22, 2026

KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 20, 2026

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - The Globe and Mail

Apr 20, 2026

KROS Rinvatercept: What to Know Before DMD Phase II Starts - Barchart

Apr 20, 2026

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView

Apr 20, 2026

Keros Therapeutics (KROS) Stock: Growth vs Risks (Momentum Fading) 2026-04-20Verified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 By Investing.com - Investing.com India

Apr 18, 2026

Apr 17, 2026

Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus

Apr 17, 2026

Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 - Investing.com

Apr 17, 2026

Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock - MarketBeat

Apr 17, 2026

[Form 4] Keros Therapeutics, Inc. Insider Trading Activity - Stock Titan

Apr 17, 2026